跳至主要内容
临床试验/NCT06336265
NCT06336265尚未招募不适用

Clinical Study of Diaphragmatic Ultrasound to Predict the Therapeutic Effect of High Flow Oxygen Therapy in Mild and Moderate Acute Hypoxic Respiratory Failure

Xingui Dai0 个研究点目标入组 269 人开始时间: 2024年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
269
主要终点
Respiratory rate

研究概览

简要总结

Follow-up was conducted for every patient requiring high-flow nasal cannula oxygen therapy in district 1 of the Intensive Care Department of Chenzhou NO.1 People's Hospital. Patients who met the inclusion criteria but did not meet the exclusion criteria were included for observation. Respiratory parameters, diaphragmatic activity, and variation rate of diaphragmatic thickness were recorded at the beginning of high-flow nasal cannula oxygen therapy, 1 hour after treatment, 3 hours after treatment, 6 hours after treatment, 9 hours after treatment, and 12 hours after treatment. Throughout the procedure, a panel of experts assessed whether the patient needed endotracheal intubation; If yes, the study was terminated; if no, high-flow nasal cannula oxygen therapy was continued, and observation and evaluation were continued until the end point of the study (12 hours after treatment). If patients or their family members do not want to continue to participate in the study during the study, they will be considered as withdrawal. If patients suffer from sudden malignant arrhythmia or cardiac arrest during the study, resulting in death or transfer to other hospitals or other departments during the study, patients will be excluded. Data from dropped and excluded patients were not included in the final statistical analysis. After the data of 269 patients were collected, the study was concluded, and the results and conclusions were derived by statistical analysis.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years old, less than 75 years old,BMI≥18.5kg/m2
  • Mild to moderate type I respiratory failure (100mmHg< PaO2/FiO2≤300mmHg)
  • Mild ventilation dysfunction (pH≥7.3)
  • Mild respiratory distress (respiratory rate > 24 times/min)
  • High-flow nasal cannula oxygen therapy is required
  • The patient and immediate family members agree and sign a written informed consent.

排除标准

  • Patients with severe type II respiratory failure, severe asthma and massive hemoptysis
  • Moderate to severe consciousness disorder, GCS score ≤12 points
  • Cardiogenic pulmonary edema and cardiogenic dyspnea caused by heart failure, heart valvular disease, myocarditis, etc
  • Hemodynamic instability, SBP< 90mmHg, or MAP<65mmHg
  • BMI < 18.5kg/m2
  • Nasal bleeding, nasal space occupying lesions, etc., can not be high-flow nasal cannula oxygen therapy through the nose or nasal obstruction
  • Patients with severe hypoxemia, severe ARDS and other conditions requiring immediate tracheal intubation
  • The patient or family member refuses to participate or does not agree to sign the written informed consent
  • The patient has participated in other research projects with interventions

结局指标

主要结局

Respiratory rate

时间窗: 0-12 hours

Respiratory rate of the patient after high-flow nasal oxygen therapy

Diaphragmatic excursion

时间窗: 0-12 hours

Diaphragmatic excursion was measured using a low-frequency curved array (" abdomen ") probe located directly below the costal arch on the midline of the clavicle.

Thickness and thickening fraction of Diaphragm

时间窗: 0-12 hours

Diaphragm thickness and thickening fraction (TFdi) were measured using a high-frequency linear array probe at the midaxillary line. TFdi = (diaphragm thickness at the end of inspirations - diaphragm thickness at the end of expirations)/diaphragm thickness at the end of expirations × 100%

Incidence of tracheal intubation

时间窗: 0-12 hours

After the patient uses high-flow nasal oxygen therapy, the panel determine whether the patient needs to undergo tracheal intubation according to the indicators such as symptoms and signs of the patient.

次要结局

未报告次要终点

研究者

发起方
Xingui Dai
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Xingui Dai

Chief Physician

First People's Hospital of Chenzhou

相似试验